Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Proteomics Scientist to Head Proteomics Discovery at Syn X Pharma

NEW YORK, Feb 6 – Toronto-based proteomics company Syn X Pharma has appointed Bradley Thatcher as vice president of proteomics discovery, Syn X said Tuesday.

Prior to joining Syn X, Thatcher was a senior field scientist specializing in proteomics and director of special projects for Ciphergen Biosystems of Fremont, Calif., where he designed systems to identify, purify, characterize and sequence proteins for development as drug candidates

Thatcher will head the discovery activities of Syn X's proteomics program, cataloging the protein changes involved in disease, the company said.

" Syn X's ability to attract a candidate of Dr. Thatcher's caliber demonstrates our commitment to being a leader in proteomics ," Sean McNicholas, Syn X CEO, said in a statement.

Syn X's flagship product, the Proteomics Discovery Platform, can be used in pre-clinical and clinical phases to identify responders and non-responders to a particular drug, or to identify patients who will benefit from a medicine earlier in the course of a disease.  

The company currently has several diagnostics in development for cardiovascular diseases including heart failure, hypertension, and diabetes, and central nervous system diseases such as Alzheimer's disease.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.